Most of the triacylglycerol (TAG) utilized for the assembly of very-low-density lipoprotein (VLDL) in the secretory apparatus of the hepatocyte is mobilized by lipolysis of the cytosolic TAG pool, followed by re-esterification. The lipases involved include arylacetamide deacetylase and/or triacylglycerol hydrolase. Some of the re-esterified products of lipolysis gain access to an apolipoprotein-B-rich VLDL precursor to form mature VLDL. Some, however, are returned to the cytosolic pool in a process that is stimulated by insulin and inhibited by microsomal triacylglycerol transfer protein (MTP). Phospholipids also contribute to VLDL TAG in a process which involves ADP-ribosylation factor-1 (ARF-1)-mediated activation of phospholipase D. The temporary storage of TAG in the liver, followed by its mobilization and secretion as VLDL, form part of a process by which the liver protects vulnerable body tissues from excess lipotoxic non-esterified ('free') fatty acids in the plasma.
Introduction
TAG (triacylglycerol) is by far the most concentrated biological fuel available and in terms of kJ/g it is considerably more energy-rich than other fuels such as carbohydrate. This high energy density makes TAG an ideal form of energy storage, particularly in higher animals which have to transport their energy reserves around with them and have to travel as light as possible. Another major advantage of TAG is that it is biologically inert. This property avoids the problems associated with its unesterified form, fatty acid, even low concentrations of which are extremely cytotoxic.
The major biological disadvantage of TAG, however, is its extreme hydrophobicity, which creates problems for its regulated transport in the polar medium of the blood plasma. To overcome these problems, vertebrates, and in particular mammals, have evolved the TAG-rich lipoproteins. These are of two types. First, the chylomicrons secreted by enterocytes of the gut in response to exogenous, or dietary, TAG and secondly, VLDL (very-low-density lipoprotein) secreted by hepatocytes of the liver in response to endogenously synthesized TAG. Most of the TAG transported in the plasma during the post-absorptive phase is associated with VLDL.
A growing body of evidence suggests that abnormalities in the size of VLDL particles secreted by the liver results in major disturbances of plasma lipoprotein metabolism [1] . These disturbances contribute to the so-called metabolic syndrome and are associated with a significant increase in cardiovascular risk [2] . The availability of TAG at specific hepatocellular sites within the secretory apparatus is a major Key words: diabetes, fatty acid, insulin, lipolysis. Abbreviations used: TAG, triacylglycerol ; VLDL, very-low-density lipoprotein ; NEFA, nonesterified fatty acid ; apoB, apolipoprotein B ; DGAT, diacylglycerol acyltransferase ; MTP, microsomal triacylglycerol transfer protein ; ARF-1, ADP-ribosylation factor 1. 1 To whom correspondence should be addressed (e-mail geoff.gibbons@mrl.ox.ac.uk).
determinant of the number and size of VLDL particles secreted into the plasma [3] . In part, this article describes the results of recent work which has highlighted several important molecular targets that appear to be responsible for regulating access of hepatic TAG into the VLDL assembly pathway. Disturbances in the behaviour of these targets arise from pathophysiological abnormalities such as diabetes and obesity. It is also becoming clear that hepatic VLDL formation plays a major role in a process by which the potential tissue lipotoxicity caused by excessive release of NEFAs (non-esterified fatty acids ; 'free fatty acids') into the plasma is effectively avoided. This review suggests how the deliberate uncoupling of TAG synthesis from TAG secretion in the liver is able to achieve this important function.
Access of TAG to an apoB (apolipoprotein B)-containing precursor is a major determinant of VLDL particle size
The fundamental framework for our understanding of the mechanism of VLDL assembly was provided by Havel and colleagues in 1976 [4] , who proposed the fusion of newly synthesized apoB with a droplet of TAG produced in the smooth endoplasmic reticulum compartment of the secretory apparatus. Several details of this process have emerged in the interim and these have been consolidated into a useful working model of VLDL assembly. This model proposes that TAG becomes associated with apoB in at least two distinct stages of the assembly process, each of which probably occurs at different locations within the hepatocellular secretory apparatus (for a review see [5] ). In the first stage, a small quantity of TAG becomes associated with apoB during its co-translational translocation through a protein channel in the membrane of the rough endoplasmic reticulum. This stage is accompanied by the acquisition of a Figure 1 Targets for the regulation of the TAG-rich particle precursor of VLDL Extracellular NEFA enter the hepatocyte from the plasma and are esterified by DGAT-1 to give TAG which is stored in the cytosol. VLDL precursor TAG is mobilized by the lipolytic action of arylacetamide deacetylase (AADA) and/or triacylglycerol hydrolase (TGH). The products of lipolysis are re-esterified by DGAT-2. Some of the product TAG is channelled into the TAG-rich VLDL precursor particle (pathway b) and some is recycled to the cytosol (pathway a). Pathway (a) is enhanced by insulin and pathway (b) by MTP. Phosphatidic acid formed by the ARF-1-mediated activation of phospholipase D (PLD) contributes TAG either to the TAG-rich VLDL precursor particle or to the mature VLDL. Potential targets for the regulation of the TAG-rich precursor are denoted by an asterisk. ER, endoplasmic reticulum ; FFA, NEFAs.
phospholipid shell or monolayer encapsulating the TAG and results in the formation of a small, dense, apoB-containing VLDL precursor in the endoplasmic reticulum ( Figure 1 ) The formation of this small precursor is dependent upon microsomal triacylglycerol transfer protein (MTP) [6, 7] , the genetic absence of which prevents the secretion of VLDL into the plasma compartment [7] . Whether this small, apo-Bcontaining precursor of VLDL remains associated with the endoplasmic reticulum membrane or becomes 'free-living' in the lumen is a matter of controversy [8] .
The bulk of the VLDL TAG is transferred during the second stage of VLDL assembly (the 'maturation' phase), which involves the fusion of the apoB-containing precursor with a larger 'droplet' of TAG. Details of this process are obscure. What is known, however, is that either the formation of the TAG-rich 'droplet' or its fusion with the apoBcontaining precursor is dependent upon the activity of ARF-1 (ADP-ribosylation factor 1), a small GTP-binding protein which activates phospholipase D [9] . GTP/GDP exchange on ARF-1 can be inhibited by brefeldin A, extremely low concentrations of which inhibit the maturation phase of VLDL assembly without affecting the formation of the apoB-containing precursor [10] . This effect of brefeldin A provides a convenient means of uncoupling the two steps of VLDL assembly so that regulation of each can be studied independently of the other. This technique has been effectively utilized to locate the site of the inhibitory effect of insulin on VLDL assembly [11] .
Of particular interest is the origin of the TAG-rich VLDL precursor required to complete the maturation phase. Its formation requires MTP [12, 13] , but the means by which it gains access to the VLDL secretory pathway is incompletely understood. This is unfortunate since, as mentioned above, the size of this secretion-coupled pool is a major determinant of the size of the VLDL particles ultimately secreted by the liver [14, 15] . It has become clear, however, that TAG newly formed via DGAT (diacylglycerol acyltransferase) from extracellular NEFA or de novosynthesized endogenous NEFA is not a direct precursor of this secretory pool [16] . Instead, most of the pool is derived via an indirect route which involves lipolytic mobilization of the bulk cytosolic storage pool of hepatocellular TAG (for a review see [3] ). The lipolytic products are then re-esterified on the luminal side of the secretory apparatus in a process which requires an isoenzyme of DGAT distinct from that involved in the esterification of extracellular fatty acids [17] . These two forms of DGAT (DGAT-1 and DGAT-2) are the products of different genes [18] , the expression of each of which is differentially regulated [19] . A number of instances have been described in which the overall rate of hepatic TAG lipolysis is positively correlated with VLDL TAG output. Thus the suppression of VLDL output by the sulphonylurea drug tolbutamide [20] , or by dietary ω − 3 fatty acids or orotic acid [21] , is associated, in each case, with a decreased VLDL TAG output. VLDL TAG secretion from the human hepatoma cell line HepG2 is virtually undetectable despite normal rates of TAG synthesis. Again, this defect is associated with an extremely low rate of cellular TAG turnover [14] . By contrast, glucose, which has long been known to stimulate VLDL output, enhances TAG lipolysis in a process which is dependent upon glucose phosphorylation by glucokinase [22] .
Details of the indirect pathway for provision of the bulk of the VLDL TAG are now beginning to emerge. First, it appears that the lipolytic mobilization of cytosolic TAG is dependent upon the activity of one or both of two recently described lipases. One of these has considerable identity with hormone-sensitive lipase but is associated with the endoplasmic reticulum [3, 23] . It was originally discovered as an activator of hepatic carcinogens and was christened arylacetamide deacetylase according to its function [24] . Transcriptional changes of the gene encoding the enzyme, measured by nuclear run-on assays, correlated well with changes in the rate of hepatic VLDL output [23] . The other lipase has been purified from hepatic endoplasmic reticulum and is known as triacylglycerol hydrolase [25] . The lipolytic products of these enzymes are re-esterified, presumably at an intracellular site accessible to the apoB-containing VLDL precursor, in a process which involves DGAT-2. Not all of this newly mobilized TAG, however, is channelled into the secretory pool which culminates in VLDL. A relatively large proportion, the size of which is determined by several factors, including both the activity of MTP and the insulin concentration to which the hepatocyte is exposed, is returned back to the cytosolic pool in what appears to be a futile cycle. The relative amounts of lipolytically mobilized TAG which enter the mutually exclusive secretory or recycling pathways can be quantified by pre-labelling the glycerol and fatty acid moieties of cytosolic TAG with different isotopes. The time-dependent relative decline in the specific radioactivity of the labelled glycerol moieties of the cellular and secreted TAG compared with those of the corresponding labelled fatty acid moiety can then be used to calculate the channelling of the newly mobilized TAG (formed by lipolysis and re-esterification) into each of the alternative pathways [20] . Insulin, which suppresses hepatic VLDL secretion by interfering with the maturation phase of VLDL assembly [11] , does not inhibit the overall lipolytic mobilization of hepatocellular cytosolic TAG. This lack of effect contrasts with its long-established inhibitory effect on TAG lipolysis in adipose tissue [3] . However, insulin appears to suppress some factor(s) which is responsible for the normal transfer of the newly mobilized TAG into the TAG-rich VLDL precursor [20] (Figure 2) . Instead, this TAG is returned back to the cytosolic pool by some constitutive, default pathway, the details of which have yet to emerge. Using a similar technique, we have also been able to show that inhibition of MTP, which is also required for the efficient production of the TAG-rich VLDL precursor [12, 13] , has, like insulin, no effect on TAG lipolysis. However, again like insulin, MTP inhibition results in the recycling of a larger quantity of this newly mobilized pool back into the cytosol, rather than into VLDL [26] (Figure 2) . Interestingly, this effect of MTP inhibition was also associated with a delay in the removal of newly synthesized apoB [27] and TAG [26] not only from endoplasmic reticulum membranes, but from the membranes of the Golgi, thus implicating the latter organelle in some process required for the maturation phase of VLDL assembly. It has also been shown that MTP, an essential component of the TAG-droplet production machinery, is present in abundance in the Golgi apparatus of TAG secretory tissues [28] .
A major advance in our understanding of the maturation phase of VLDL assembly arose from studies by Olofsson and colleagues who showed that either the formation of the TAG-rich VLDL precursor or its fusion with the apoBrich precursor was dependent upon the activity of ARF-1, a small GTP-binding protein [9, 29] . Using a cell-free system which was able to assemble VLDL from apoB, these workers showed that hydrolysis of GTP on ARF-1 was responsible for the activation of phospholipase D, which produces the TAG precursor phosphatidic acid from phosphatidylcholine. Previous studies from our own laboratory have provided strong evidence that a sizable proportion of VLDL TAG arose from cellular phospholipid fatty acids [30] . The ARF-1-dependent, phospholipase D-mediated formation of phosphatidic acid provides a plausible mechanism for the above observation.
Defective regulation of hepatic VLDL synthesis
As mentioned above, insulin directly inhibits hepatic VLDL assembly by interfering with the recruitment of intracellular TAG. This effect, first described by Durrington and colleagues over 20 years ago [31] , is now generally considered to have a major physiological impact on the regulation of plasma TAG concentrations, particularly in the post-prandial state (for reviews see [32, 33] ). It was also suggested that impairment of insulin action at the hepatic level would result in a failure to suppress VLDL output, an effect which contributed to the high levels of VLDL secretion commonly observed in obese insulin-resistant subjects or in subjects with Type II diabetes [34] . We tested this hypothesis using cultured hepatocytes from several animal models of insulin resistance, including those from obese Zucker rats (for a review see [33] ). In every case, the basal rates of VLDL secretion (measured in the absence of insulin) were higher than those observed in hepatocyte cultures from the corresponding control donor animals. Furthermore, insulin also failed to suppress the secretion of VLDL TAG and apoB to the same extents as in the control hepatocytes. Interestingly, hepatocytes cultured from the obese Zucker rats for longer periods of time exhibited neither a high basal level of VLDL output nor an attenuated inhibitory response to insulin. It was concluded that the 'obese' hepatocytes were not inherently insulin-resistant and that their insulin-insensitivity derived exclusively from the environment to which the liver was exposed in vivo. Normal insulin sensitivity could be restored by exposure to a suitable environment in vitro. To test the hypothesis that the initial insulin insensitivity of the 'obese' hepatocytes was a consequence of the chronically high insulin concentration to which the liver was exposed in vivo, hepatocytes were prepared form normal rats in which insulin had been chronically infused by implanted mini-pumps over periods of 7 and 14 days [35] . Although these primary cultures secreted a higher basal amount of VLDL, they showed normal sensitivity to the inhibitory effect of insulin in vitro. From this series of experiments we concluded that although chronic exposure of the liver to insulin enhanced VLDL output it did not, in itself, increase resistance to the normal direct inhibitory effect of insulin. Thus the resistance exhibited in this respect by the hepatocytes from the obese Zucker rats was due to some factor other than the chronic hyperinsulinaemia to which the livers of these animals were exposed in vivo.
The relevance of these observations in animal models for studies of insulin resistance in humans has been highlighted by experiments in subjects with Type II diabetes [36, 37] . During a hyperinsulinaemic/euglycaemic clamp, there was very little suppression of newly synthesized hepatic apoB secretion in these subjects compared with controls. This lack of effect was most pronounced on the production of the large (VLDL-1) rather than on the small (VLDL-2) particles [37] . A similar ineffectiveness of insulin on the secretion of VLDL TAG and apoB has been observed during hyperinsulinaemic/euglycaemic-clamp experiments in obese subjects. This lack of effect could not be wholly attributed to changes in hepatic fatty acid supply [36] .
Why does the liver need to secrete VLDL?
We will conclude this review with a few speculative remarks concerning the purpose of hepatic VLDL production. For many years it has been thought that the major role of VLDL is the transport of hepatic fatty acids synthesized de novo, for storage in adipose tissue depots. Thus VLDL was thought to play a major role in the whole-body conversion of dietary carbohydrate into stored TAG. A recent report has suggested the possibility that glycaemia is regulated partly by conversion of excess dietary carbohydrate into hepatic fatty acids (via the acetyl-CoA/malonyl-CoA pathway) followed by secretion as VLDL TAG [38] . According to this view, hypertriglyceridaemia is sometimes the price which has to be paid for effective control of the plasma glucose concentration. An additional, or alternative, role is suggested by the fact that, even under conditions in which hepatic de novo lipogenesis is high, in both rodents and in humans most of the hepatic VLDL TAG is not derived from this source [39, 40] . In this context, the precise function of hepatic de novo lipogenesis has yet to be resolved [40] . A clue to the identification of such an alternative function for VLDL may be provided by the observation that by far the greatest amount of VLDL TAG is ultimately synthesized from pre-formed fatty acids entering the liver from adipose tissue [39] . But why are these fatty acids simply returned back to adipose tissue via lipoprotein lipase as part of an apparent futile cycle with little quantitative significance for whole-body energy balance? The answer to this paradox may be found in the context of one of the liver's functions in neutralizing the potential toxicity both of exogenous xenobiotics (including alcohol) and of endogenous metabolites. In this respect, it could be argued that the liver detoxifies potentially malignant by-products of lipid metabolism such as low-density lipoprotein and chylomicron remnants. Taking the argument a step further, the liver also neutralizes the potent cytotoxicity of fatty acids by transforming them into the chemically inert and biologically benign derivative TAG. TAG formation from extracellular NEFAs would be enhanced by a high rate of de novo lipogenesis and thus high malonyl-CoA concentration [41] in an integrated process which would inhibit fatty acid oxidation and link the regulation of glycaemia [38] with that of plasma NEFA concentration.
The need for rigorous control of plasma NEFA concentrations arises from the release of fatty acid from adipose tissue in amounts which exceed the fatty acid oxidative capacity of energy-requiring tissues. Such fatty acids are released not only as a result of hormone-sensitive lipase activity on TAG stored within adipose tissue, but also from the lipoprotein lipase-mediated lipolysis of chylomicron and VLDL TAG, of which, not all the resulting fatty acids enter adipose tissue for esterification [42] . Hepatic esterification and temporary storage of these fatty acids as TAG provides an effective buffer by which plasma NEFA concentrations can be modulated effectively. The capacity of the liver for TAG storage, although quite large [3] , is not limitless. Thus TAG, temporarily stored in the liver, is hydrolysed and reconstituted as VLDL which is then secreted. In this way hepatic TAG synthesis and storage is effectively decoupled from secretion as part of a process which ensures that stored TAG is only mobilized for VLDL assembly under conditions which do not exacerbate post-prandial hyperlipidaemia. Evidence for such a rhythmic non-superimposable pattern of hepatic TAG synthesis and secretion has recently been presented in human subjects [43, 44] .
Concluding remarks
This brief report attempts to summarize our current understanding of the synthesis and functions of VLDL. Recent work has highlighted several molecular targets which are crucial for the normal recruitment of intracellular lipids for VLDL assembly. Abnormal regulation of these targets often results in the overproduction of VLDL, particularly of the larger particles. Many aspects of VLDL assembly remain obscure and several questions remain to be answered. These include: (a) What is the precise mechanism by which cytosolic TAG is transferred into the secretory apparatus? (b) What is the role of phospholipids in this process? (c) What is the precise molecular target of insulin action? (d) Which intracellular site is responsible for the bulk transfer of TAG to the maturing VLDL? It is clear that much of the detailed enzymology involved in VLDL synthesis remains to be discovered. Elucidation of these pathways is crucial for a complete understanding of the causes both of abnormal lipoprotein metabolism and of non-alcoholic fatty liver disease.
